The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment seeking daily smokers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
62
2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
Placebo
Yale Center for Clinical Investigation, Yale University
New Haven, Connecticut, United States
Latency to Initiate Ad-lib Smoking Session
minutes to start smoking (range 0 to 50 minutes)
Time frame: 0 to 50 minutes
Number of Cigarettes Smoked During the 60 Minute Ad-lib Period
number of cigarettes smoked (range 0-8) during the 60 minute ad-lib period
Time frame: 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.